Thymosin Beta-4 (Fragment)
Also known as: TB4-Frag, Ac-SDKP, N-Acetyl-Seryl-Aspartyl-Lysyl-Proline
The TB-4 fragment (Ac-SDKP) is the active anti-fibrotic and cardioprotective component of Thymosin Beta-4. While full TB-500 handles actin sequestration and cell motility, Ac-SDKP specifically inhibits TGF-β-driven fibrosis and inflammation. It naturally circulates in blood and is regulated by ACE (angiotensin-converting enzyme).
Regulatory & Approval Status
Also known as TB-500, this fragment has no published human clinical trials and is not FDA-approved. While a July 2026 FDA advisory committee voted 8-6 to recommend it for compounding, the FDA has not yet acted on this recommendation.
Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.